• Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 580.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.25
▼ -0.1 (-7.41%)

This chart shows the closing price for RNXT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New RenovoRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNXT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNXT

Analyst Price Target is $8.50
▲ +580.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for RenovoRx in the last 3 months. The average price target is $8.50, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 580.00% upside from the last price of $1.25.

This chart shows the closing price for RNXT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in RenovoRx. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2024Alliance Global PartnersInitiated CoverageBuy$4.00Low
11/15/2023Maxim GroupReiterated RatingBuy ➝ HoldLow
8/18/2023Roth MkmLower TargetBuy ➝ Buy$14.00 ➝ $13.00Low
11/1/2021Roth CapitalInitiated CoverageBuy$16.00High
10/6/2021Maxim GroupInitiated CoverageBuy$15.00Medium
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
RenovoRx logo
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.
Read More

Today's Range

Now: $1.25
Low: $1.20
High: $1.35

50 Day Range

MA: $1.30
Low: $1.14
High: $1.47

52 Week Range

Now: $1.25
Low: $0.53
High: $3.29

Volume

29,650 shs

Average Volume

50,281 shs

Market Capitalization

$29.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of RenovoRx?

The following Wall Street analysts have issued reports on RenovoRx in the last twelve months: Alliance Global Partners, Maxim Group, and Roth Mkm.
View the latest analyst ratings for RNXT.

What is the current price target for RenovoRx?

2 Wall Street analysts have set twelve-month price targets for RenovoRx in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 580.0%. Roth Mkm has the highest price target set, predicting RNXT will reach $13.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $4.00 for RenovoRx in the next year.
View the latest price targets for RNXT.

What is the current consensus analyst rating for RenovoRx?

RenovoRx currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RNXT.

What other companies compete with RenovoRx?

How do I contact RenovoRx's investor relations team?

RenovoRx's physical mailing address is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. The company's listed phone number is 650-284-4433 and its investor relations email address is [email protected]. The official website for RenovoRx is www.renovorx.com. Learn More about contacing RenovoRx investor relations.